Reduced Dose of PTCy Followed by Adjuvant α-Galactosylceramide Enhances GVL Effect without Sacrificing GVHD Suppression

Researchers investigated the effects of reducing the dose of posttransplantation cyclophosphamide (PTCy) followed by α-galactosylceramide, a ligand of iNKT cells, on the reciprocal balance between graft-versus-host disease (GVHD) and the graft-versus-leukemia (GVL) effect.